Daniel Parra González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel Parra González has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Edelberto Silva
Department of Pharmacy, Faculty of Sciences, Universidad Nacional de Colombia, Bogotá 111321, Colombia
2 shared publications - Jorge Alberto Cortés
Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Sede Bogotá, Bogotá 111321, Colombia
2 shared publications - Jorge Augusto Díaz Rojas
Universidad Nacional de Colombia
2 shared publications - Julio César Gómez-Rincón
Grupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia; Grupo de Investigación Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Instituto Nacional de Cancerología, Bogotá, D. C., Colombia; Facultad de Medicina, Universidad El Bosque, Bogotá, D. C., Colombia
2 shared publications - Sonia Isabel Cuervo-Maldonado
Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia
2 shared publications - Carlos Humberto Saavedra
Universidad Nacional de Colombia - Sede Bogotá - Facultad de Medicina - Departamento de Medicina Interna - Bogotá D.C. - Colombia. | Hospital Universitario Nacional de Colombia - Proceso de Atención Hospitalaria - Bogotá D.C. - Colombia
1 shared publication
Latest Publications
- Open Access
- 6 March 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 1513
Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping review
Background Vancomycin is an effective first-line therapy primarily in methicillin-resistant Staphylococcus aureus (MRSA) infection and Clostridium difficile, however, it has been shown that its effectiveness and the reduction of nephrotoxicity depend on maintaining adequate therapeutic levels. Population pharmacokinetic (PopPk) models attempt to parameterize the behavior of plasma concentrations in different target populations and scenarios such as renal replacement therapy, to successful therapeutic outcome and avoid these side effects. Methods A scoping review was conducted following the guidelines of Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR), through a search in PubMed, LILACS, OVID Medline, Scopus, Web of Science, SAGE Journals, Google Scholar and previous known registers of PopPk models in non-critically ill adult patients, published between 1998 and 2024. Results A total of 190 papers were fully screened, of which were included 36 studies conducted in different populations; 12 in general population, 23 in special populations (surgical, with impaired renal function, obese, elderly, with cancer and cystic fibrosis), and 1 in mixed population (general and with cancer). The main parameters in the models were renal clearance and volume of distribution. The principal covariables that affected the models were creatinine clearance and weight. All studies used internal evaluation and 4 of them used an external group. Discussion The technology for the development and implementation of PopPk models requires experts in clinical pharmacology and is limited to university and research centers. The software is mostly expensive and, in most cases, the pharmacokinetic models and the heterogeneity in the parameters and evaluation methods depend on which compartmental model, parameters, covariates and software have been used. Conclusions These models require validation in the clinical context and conducting experiments to adapt them for precision dosing in different subpopulations.
- 6 March 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 1513
Open AccessVancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping review
Background Vancomycin is an effective first-line therapy primarily in methicillin-resistant Staphylococcus aureus (MRSA) infection and Clostridium difficile, however, it has been shown that its effectiveness and the reduction of nephrotoxicity depend on maintaining adequate therapeutic levels. Population pharmacokinetic (PopPk) models attempt to parameterize the behavior of plasma concentrations in different target populations and scenarios such as renal replacement therapy, to successful therapeutic outcome and avoid these side effects. Methods A scoping review was conducted following the guidelines of Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR), through a search in PubMed, LILACS, OVID Medline, Scopus, Web of Science, SAGE Journals, Google Scholar and previous known registers of PopPk models in non-critically ill adult patients, published between 1998 and 2024. Results A total of 190 papers were fully screened, of which were included 36 studies conducted in different populations; 12 in general population, 23 in special populations (surgical, with impaired renal function, obese, elderly, with cancer and cystic fibrosis), and 1 in mixed population (general and with cancer). The main parameters in the models were renal clearance and volume of distribution. The principal covariables that affected the models were creatinine clearance and weight. All studies used internal evaluation and 4 of them used an external group. Discussion The technology for the development and implementation of PopPk models requires experts in clinical pharmacology and is limited to university and research centers. The software is mostly expensive and, in most cases, the pharmacokinetic models and the heterogeneity in the parameters and evaluation methods depend on which compartmental model, parameters, covariates and software have been used. Conclusions These models require validation in the clinical context and conducting experiments to adapt them for precision dosing in different subpopulations.
- Open Access
- 1 November 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1523
Pharmacokinetics of Vancomycin among Patients with Chemotherapy-Associated Febrile Neutropenia: Which Would Be the Best Dosing to Obtain Appropriate Exposure?
Previous research has determined that the required doses for treating febrile neutropenia with vancomycin are higher than the doses used conventionally. These recommendations have been made considering pharmacotherapeutic goals based on minimum concentration () between 15–20 . This study was developed to evaluate dose recommendations based on the achievement of a target consisting of ratio of area under the curve over minimum inhibitory concentration () in this population of individuals. This study was conducted in a referral hospital for cancer treatment, study participants received vancomycin doses of every 12 h in 2-4-h infusions. Vancomycin was described by a two-compartment pharmacokinetic model with clearance dependent on the estimated glomerular filtration rate. Simulations were performed taking into account a reduced version of the model to establish the influence of controllable and non-controllable variables on the probability of achieving several PK-PD targets. A dose of in patients with estimated glomerular filtration rate () between 80 and was adequate to achieve the pharmacotherapeutic target. A discrepancy was found between -based and -based PK/PD indices, the former being affected by the dose and creatinine clearance while the latter highly influenced by the interval between doses.- 1 November 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1523
Open AccessPharmacokinetics of Vancomycin among Patients with Chemotherapy-Associated Febrile Neutropenia: Which Would Be the Best Dosing to Obtain Appropriate Exposure?
Previous research has determined that the required doses for treating febrile neutropenia with vancomycin are higher than the doses used conventionally. These recommendations have been made considering pharmacotherapeutic goals based on minimum concentration () between 15–20 . This study was developed to evaluate dose recommendations based on the achievement of a target consisting of ratio of area under the curve over minimum inhibitory concentration () in this population of individuals. This study was conducted in a referral hospital for cancer treatment, study participants received vancomycin doses of every 12 h in 2-4-h infusions. Vancomycin was described by a two-compartment pharmacokinetic model with clearance dependent on the estimated glomerular filtration rate. Simulations were performed taking into account a reduced version of the model to establish the influence of controllable and non-controllable variables on the probability of achieving several PK-PD targets. A dose of in patients with estimated glomerular filtration rate () between 80 and was adequate to achieve the pharmacotherapeutic target. A discrepancy was found between -based and -based PK/PD indices, the former being affected by the dose and creatinine clearance while the latter highly influenced by the interval between doses. - Open Access
- 29 April 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (5) , 504
Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
Patients with chemotherapy-induced febrile neutropenia (CIFN) may have changes in the pharmacokinetics (PK) compared to patients without malignancies or neutropenia. Those changes in antibiotic PK could lead to negative outcomes for patients if the therapy is not adequately adjusted to this. In this, open-label, non-randomized, prospective, observational, and descriptive study, a PK model of cefepime was developed for patients with hematological neoplasms and post-chemotherapy febrile neutropenia. This study was conducted at a cancer referral center, and study participants were receiving 2 g IV doses of cefepime every 8 h as 30-min infusions. Cefepime PK was well described by a two compartment model with a clearance dependent on a serum creatinine level. Using Monte Carlo simulations, it was shown that continuous infusions of 6g q24h could have a good achievement of PK/PD targets for MIC levels below the resistance cut-off point of Enterobacteriaceae. According to the simulations, it is unnecessary to increase the daily dose of cefepime (above 6 g daily) to increase the probability of target attainment (PTA). Cumulative fraction of response (CFR) using interment dosing was suboptimal for empirical therapy regimens against K. pneumoniae and P. aeruginosa, and continuous infusions could be used in this setting to maximize exposure. Patients with high serum creatinine levels were more likely to achieve predefined PK/PD targets than patients with low levels.
- 29 April 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (5) , 504
Open AccessPharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
Patients with chemotherapy-induced febrile neutropenia (CIFN) may have changes in the pharmacokinetics (PK) compared to patients without malignancies or neutropenia. Those changes in antibiotic PK could lead to negative outcomes for patients if the therapy is not adequately adjusted to this. In this, open-label, non-randomized, prospective, observational, and descriptive study, a PK model of cefepime was developed for patients with hematological neoplasms and post-chemotherapy febrile neutropenia. This study was conducted at a cancer referral center, and study participants were receiving 2 g IV doses of cefepime every 8 h as 30-min infusions. Cefepime PK was well described by a two compartment model with a clearance dependent on a serum creatinine level. Using Monte Carlo simulations, it was shown that continuous infusions of 6g q24h could have a good achievement of PK/PD targets for MIC levels below the resistance cut-off point of Enterobacteriaceae. According to the simulations, it is unnecessary to increase the daily dose of cefepime (above 6 g daily) to increase the probability of target attainment (PTA). Cumulative fraction of response (CFR) using interment dosing was suboptimal for empirical therapy regimens against K. pneumoniae and P. aeruginosa, and continuous infusions could be used in this setting to maximize exposure. Patients with high serum creatinine levels were more likely to achieve predefined PK/PD targets than patients with low levels.